Topical intranasal corticosteroids (INS) are the most effective treatment f
or allergic rhinitis and are being increasingly prescribed to children. Due
to the potent inhibition of childhood growth seen with oral corticosteroid
s, it is important to examine whether INS could have similar effects. The e
vidence available suggests that some INS, such as beclomethasone dipropiona
te (BDP), may slow growth when used regularly for prolonged periods. Howeve
r, newer INS such as fluticasone propionate (FP) and mometasone furoate, wh
ich have substantially reduced bioavailability via gastrointestinal absorpt
ion, are unlikely to do so. Well-designed prospective studies are needed to
distinguish those INS with reduced or absent effects on growth. In practic
e, choosing an INS which optimises the ratio of therapeutic effect to syste
mic bioavailability will probably reduce the risk of growth suppression to
a negligible level.